Antiviral PROTACs: Opportunity borne with challenge

Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of the ubiquitin-proteasome-system has become a promising strategy in drug design. The overwhelming advantages of PROTAC technology have ensured a rapid and wide usage, and multiple PROTACs have entered clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jinsen, Wu, Yihe, Lan, Ke, Dong, Chune, Wu, Shuwen, Li, Shu, Zhou, Hai-Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308200/
https://www.ncbi.nlm.nih.gov/pubmed/37398636
http://dx.doi.org/10.1016/j.cellin.2023.100092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308200/
https://www.ncbi.nlm.nih.gov/pubmed/37398636
http://dx.doi.org/10.1016/j.cellin.2023.100092

Ejemplares similares